---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-25-000011"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2025-06-06T23:59:59+00:00"
generated_at: "2026-05-19T18:25:01.522552+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# NovoCure shareholders elect 11 directors, approve ESPP; President awarded 179,426 RSUs

## Summary
- Shareholders elected all 11 director nominees with >81M votes each; 92.98M shares represented (~83.4%).
- Say-on-pay approved: 80.6M for, 2.0M against, ~10M broker non-votes.
- 2025 Employee Share Purchase Plan approved: 82.0M for, 0.68M against; reserves 6,507,843 shares (less prior plan shares).
- Francis Leonard appointed President, Novocure and awarded 179,426 RSUs vesting in two equal annual installments.

## SEC filing metadata
- accession: 0001645113-25-000011
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2025-06-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000011/0001645113-25-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000011/nvcr-20250604.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-25-000011
- JSON: https://secwatch.observer/filing/0001645113-25-000011.json
- Plain text: https://secwatch.observer/filing/0001645113-25-000011.txt

## Key facts
- Executive change
  Francis Leonard was appointed as President, Novocure at NovoCure Ltd.
  - Action: appointed
  - Role: President, Novocure
  source text: In connection with his appointment of the title "President, Novocure" on June 4, 2025 (the "Award Date"), Francis Leonard, formerly the Company's Executive Vice President, President Novocure Oncology, was awarded 179,426 Restricted Share Units
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000011/0001645113-25-000011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.